Kancera’s fractalkine-blocking candidate cleared in Finland for phase I trial
Oct. 24, 2023
The Finnish regulatory agency (FIMEA) has approved Kancera AB’s application to conduct a phase I study of KAND-145, the company’s second-generation fractalkine-blocking candidate drug for cancer.
